Abstract
Although there is substantial evidence for direct, in vitro opioid effects on the immune system, radioligand binding studies have not definitively described brain opioid receptors on these cells (1). It is possible that the density of receptors required for immunomodulation is too low to detect with radioligands, or that only a small percentage of cells may express opioid receptors in heterogeneous leukocyte populations. In addition, the level of receptor expression in leukocytes may depend on the developmental stage or the activation state of the cells. The use of fluorescent opioid ligands would allow visualization of opioid receptors by microscopy, analysis of cell subpopulations for opioid receptor expression, or separation of cells expressing opioid receptors by flow cytometry. Several groups have synthesized fluorescent opioid probes, using fluorophores such as 1-dimethylaminonaphthalene-5-sulfonic acid (dansyl) (2, 3), rhodamine (4, 5), fluorescein (5), pyrene (6), and nitrobenzodiazole (7). Although these compounds showed high affinity and biological activity at opioid receptors, the peak emission wavelengths of some may overlap with autofluorescence (3). In addition, irradiation at wavelengths near the excitation peak for dansyl compounds can greatly reduce opioid receptor affinity by irreversibly altering the structures of opioid receptors and ligands (8). The longer excitation and emission wavelengths of the rhodamine-and fluorescein-labeled opioid probes (4, 5) avoid the problems of irradiation-induced receptor alteration and tissue autofluo-rescence, but specific histological labeling of opioid receptors with these fluorescent ligands has not been demonstrated.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
N. E. S. Sibinga and A. Goldstein, Opioid peptides and opioid receptors in cells of the immune system, Annu. Rev. Immunol. 6:219–249 (1988).
M. C. Foumie-Zaluski, G. Gacel, B. P. Rogues, B. Senault, J. M. Lecomte, B. Malfroy, J. P. Swats, J. P., and J. C. Schwartz, Fluorescent enkephalin derivatives with biological activity, Biochem. Biophys. Res. Commun. 83:300–305 (1978).
F. M. A. Corréa, R. B. Innis, B. Rouot, G. W. Pasternak, and S. H. Snyder, Fluorescent probes of α-and β-adrenergic and opiate receptors: biochemical and histochemical evaluation, Neurosci. Lett. 16:47–53 (1980).
E. Hazum, K.-J. Chang, Y. Shechter, S. Wilkinson, and P. Cuatrecasas, Fluorescent and photo-affinity enkephalin derivatives: preparation and interaction with opiate receptors, Biochem. Biophys. Res. Commun. 88:841–846 (1979).
V. M. Kolb, A. Koman, and L. Terenius, Fluorescent probes for opiate receptors, Life Sci. 33(Suppl. 1): 423–426 (1983).
H. Mihara, S. Lee, Y. Shimohigashi, H. Aoyagi, T. Kato, N. Izumiya, and T. Costa, δ and u. opiate receptor probes: fluorescent enkephalins with high receptor affinity and specificity, FEBS Lett. 193:35–38 (1985).
S. Archer, F. Medzihradsky, A. Seyed-Mozaffari, and P. J. Emmerson, Synthesis and characterization of 7-nitrobenzo-2-oxa-1,3-diazole (NBD)-labeled fluorescent opioids, Biochem. Pharmacol. 43:301–306 (1992).
J. A. Glasel and R. F. Venn, The sensitivity of opiate receptors and ligands to short wavelength ultraviolet light, Life Sci. 29:221–228 (1981).
J. M. Bidlack, L. D. Saripalli, and D. M. P. Lawrence, κ-Opioid binding sites on a murine lymphoma cell line, Eur. J. Pharmacol. 227:257–265 (1992).
D. M. P. Lawrence and J. M. Bidlack, The kappa opioid receptor expressed on the mouse R1.1 thymoma cell line is coupled to adenylyl cyclase through a pertussis toxin-sensitive guanine nucleotide-binding regulatory protein, J. Pharmacol. Exp. Ther 266:1678–1683.
D. M. P. Lawrence, D. B. Joseph and J. M. Bidlack, Kappa opioid receptors expressed on three related thymoma cell lines: differences in receptor-effector coupling, Biochem. Pharmacol. 49:81–89 (1995).
J. J. Barlow, T. P. Blackburn, G. F. Costello, R. James, D. J. Le Count, B. G. Main, R. J. Pearce, K. Russel, and J. S. Shaw, Struc.are/activity studies related to 2-(3,4-dichloropheny1)-N-methyl-N-[2-(1-pyrrolid-iny1)-1-substituted-ethyl]acetamides: a novel series of potent and selective κ-opioid agonists, J. Med. Chem. 34:3149–3158 (1991).
R. A. Mathies and L. Stryer, Single-molecule fluorescence detection: a feasibility study using phycoerythrin, in: “Applications of Fluorescence in the Biomedical Sciences,” D. L. Taylor, A. S. Waggoner, R. F. Murphy, F. Lanni and R. R. Birge, eds., Alan Liss, Inc., New York (1986).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media New York
About this chapter
Cite this chapter
Lawrence, D.M.P., Archer, S., Bidlack, J.M. (1995). Identification of Opioid Receptors in the Immune System Using a Novel Combination of Selective Opioid Ligands and Indirect Phycoerythrin Immunofluorescence. In: Sharp, B.M., Eisenstein, T.K., Madden, J.J., Friedman, H. (eds) The Brain Immune Axis and Substance Abuse. Advances in Experimental Medicine and Biology, vol 373. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1951-5_3
Download citation
DOI: https://doi.org/10.1007/978-1-4615-1951-5_3
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5801-5
Online ISBN: 978-1-4615-1951-5
eBook Packages: Springer Book Archive